2018 Volume 121 Issue 12 Pages 1486-1492
The objective of this study was to evaluate the adverse events and efficacy of treatment with the combination regimen of docetaxel, cisplatin, and 5-fluorouracil (TPF) in patients with head and neck cancer.
We retrospectively analyzed the data of 82 patients with locally advanced head and neck cancer who underwent treatment with TPF between January 2012 and December 2014. We investigated the early and late toxicities and efficacy of the treatment. The 3-year overall survival rate was 70.7%, the locoregional control rate was 64%, and the disease-free survival rate was 62.8%. Grade≧3 neutropenia was observed in 82.9% of the patients (n=68) and febrile neutropenia (FN) was observed in 51.2% of the patients (n=42). The late toxicity rate may be lower than that reported previously.
TPF-CCRT treatment compared rather favorably with CDDP-CCRT treatment. The incidence of FN was higher than 20%, and the prophylactic use of granulocyte-colony stimulating factor (G-CSF) was necessary. Serious adverse events are commonly observed in patients undergoing treatment with TPF; hence, this treatment should be provided in experience-rich facilities.
